At present, the main therapeutic strategies for targeting WNT signaling in CRC are focused on inhibiting CTNNB1 expression and protein accumulation, because 75% of CRC patients have APC mutation [2,3]. Here, CTNNB1 is linked to colorectal carcinoma.